Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gain Therapeutics Inc (NQ: GANX )

4.860 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 4.860
Bid (Size) 4.750 (20)
Ask (Size) 5.200 (4)
Prev. Close 4.860
Today's Range 4.860 - 4.860
52wk Range 2.800 - 6.190
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Gain Therapeutics to Present at the Jefferies Healthcare Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Chardan Capital Maintains Buy Rating for Gain Therapeutics: Here's What You Need To Know
 
Via Benzinga

Performance

YTD
+50.00%
+50.00%
1 Month
-8.65%
-8.65%
3 Month
+27.23%
+27.23%
6 Month
+48.62%
+48.62%
1 Year
+43.79%
+43.79%

More News

Read More
Where Gain Therapeutics Stands With Analysts
Via Benzinga
Analyst Expectations for Gain Therapeutics's Future
Via Benzinga
Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Expert Ratings for Gain Therapeutics
Via Benzinga
Analyst Ratings for Gain Therapeutics
Via Benzinga
Gain Therapeutics Touts Additional Encouraging Preclinical Data For Lead Parkinson's Program
Via Benzinga
Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Presents New Preclinical Data from its Gaucher Disease Program at the 19th Annual WORLDSymposium
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Present at Sidoti Small-Cap Virtual Investor Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Medtronic To $85? Plus Oppenheimer Slashes PT On This Stock By 67%
Via Benzinga
Heska To $165? Plus BTIG Cuts PT On This Stock By 67%
Via Benzinga
AMD To Rally Around 39%? Here Are 5 Other Price Target Changes For Monday
Via Benzinga
Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2022
Via Benzinga
Apple To $185? Here Are 5 Other Price Target Changes For Friday
Via Benzinga
Gain Therapeutics: Reasons For Optimism
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.